Who are Ilaprazole + Amoxicillin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): omeprazole plus amoxicillin, Rabeprazole, Amoxicillin, vonoprazan fumarate + amoxicillin（H-14d).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ilaprazole-amoxicillin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Ilaprazole + Amoxicillin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ilaprazole + Amoxicillin (Ilaprazole + Amoxicillin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proton pump inhibitor + Beta-lactam antibiotic combination. Area: Gastroenterology.

marketed Proton pump inhibitor + Beta-lactam antibiotic combination H+/K+-ATPase (ilaprazole); Bacterial cell wall peptidoglycan (amoxicillin) Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Ilaprazole + Amoxicillin (Ilaprazole + Amoxicillin) — Il-Yang Pharm. Co., Ltd.. Ilaprazole inhibits gastric acid secretion while amoxicillin kills Helicobacter pylori bacteria, together eradicating H. pylori infection and healing peptic ulcers.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ilaprazole + Amoxicillin TARGET	Ilaprazole + Amoxicillin	Il-Yang Pharm. Co., Ltd.	marketed	Proton pump inhibitor + Beta-lactam antibiotic combination	H+/K+-ATPase (ilaprazole); Bacterial cell wall peptidoglycan (amoxicillin)
omeprazole plus amoxicillin	omeprazole plus amoxicillin	National Taiwan University Hospital	marketed	Proton pump inhibitor + beta-lactam antibiotic combination	Proton pump (H+/K+-ATPase) and bacterial cell wall (penicillin-binding proteins)
Rabeprazole, Amoxicillin	Rabeprazole, Amoxicillin	Mackay Memorial Hospital	marketed	Proton pump inhibitor + Beta-lactam antibiotic combination	H+/K+-ATPase (rabeprazole); Bacterial penicillin-binding proteins (amoxicillin)
vonoprazan fumarate + amoxicillin（H-14d)	vonoprazan fumarate + amoxicillin（H-14d)	Sixth Affiliated Hospital, Sun Yat-sen University	phase 3	Proton pump inhibitor + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall (amoxicillin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proton pump inhibitor + Beta-lactam antibiotic combination class)

Il-Yang Pharm. Co., Ltd. · 1 drug in this class
Mackay Memorial Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ilaprazole + Amoxicillin — Competitive Intelligence Brief. https://druglandscape.com/ci/ilaprazole-amoxicillin. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing